Phototoxic Dermatitis by Gonçalo, Margarida
Metadata of the chapter that will be visualized online
Chapter Title Phototoxic Dermatitis
Copyright Year 2011
Copyright Holder Springer-Verlag Berlin Heidelberg




Division/Department Clinic of Dermatology, Coimbra University
Hospital
Organization/University University of Coimbra







Abstract • Phototoxic dermatitis from exogenous chemicals can be polymorphic.
• It is not always easy to distinguish phototoxicity from photoallergy.
• Phytophotodermatitis from plants containing furocoumarins is one of the
main causes of phototoxic contact dermatitis.
• Topical and systemic drugs are a frequent cause of photosensitivity, often
with phototoxic aspects.
• The main clinical pattern of acute phototoxicity is an exaggerated sunburn.
• Subacute phototoxicity from systemic drugs can present as
pseudoporphyria, photoonycholysis, and dyschromia.
• Exposure to phototoxic drugs can enhance skin carcinogenesis.
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4 Core Messages
5 ● Phototoxic dermatitis from exogenous chemicals can
6 be polymorphic.
7 ● It is not always easy to distinguish phototoxicity from
8 photoallergy.
9 ● Phytophotodermatitis from plants containing
10 furocoumarins is one of the main causes of phototoxic
11 contact dermatitis.
12 ● Topical and systemic drugs are a frequent cause of
13 photosensitivity, often with phototoxic aspects.
14 ● The main clinical pattern of acute phototoxicity is an
15 exaggerated sunburn.
16 ● Subacute phototoxicity from systemic drugs can present
17 as pseudoporphyria, photoonycholysis, and dyschromia.




21 Photosensitivity represents an abnormal inflammatory
22 skin reaction to the sun, presenting under a wide spectrum
23 of clinical reaction patterns. It is usually due to the abnor-
24 mal presence, in the skin, of an endogenous or exogenous
25 substance that is selectively activated by solar radiation –
26 a chromophore. ApartAu2 from exogenous photoactive
27 chemicals, there are several causes for photosensitivity:
28 congenital or acquired errors may hinder DNA repair
29 after ultraviolet (UV) aggression (xeroderma
30 pigmentosum, Bloom’s syndrome) and reduce the natural
31 UV protection (albinism and vitiligo) or the antioxidative
32 response to UV light (pellagra due to reduced levels of
33 niacin in diet or from alcohol consumption); accumula-
34 tion of endogenous photoactive chemicals, like in por-
35 phyria; idiopathic photodermatosis, inflammatory or
36 immune-mediated reactions whose antigen has not been
37 well characterized, like solar urticaria, polymorphos light
38 eruption, ‘‘lucite estvial benigne,’’ actinic prurigo, and
39 chronic actinic dermatitis (Hawk 1999).
40 Considering only photosensitivity from exogenous
41 agents, both chemicals applied topically or those that
42 reach the skin by the systemic route, there is still a wide
43 spectrum of skin reactions. Some involve predominantly
44 a specific T-cell-dependent response, including
45photoallergy, both photoallergic contact dermatitis and
46systemic photoallergy, and autoimmunity with photosen-
47sitivity, as in drug-induced photosensitive lupus
48erythematosus in Ro-positive patients taking terbinafine,
49thiazide diuretics, calcium channels blockers, or taxanes
50(Farhi et al. 2006; Sontheimer et al. 2008; Cohen 2009).
51Phototoxic dermatitis, on the other hand, does not involve
52specific immune hypersensitivity reactions.
53Although these mechanisms are well characterized, their
54participation in each case of photosensitivity can be more
55complex. For instance, in chronic actinic dermatitis,
56the extreme photosensitivity to UV light may be initially
57triggered by a photosensitive reaction or by contact allergy
58to perfumes, sesquiterpene lactones, or colophony, but in its
59evolution, individuals become extremely photosensitive even
60with no further exposure to an exogenous chromophore or
61allergen: An autoantigen may have been formed during the
62acute reaction (DNA or RNA modified by plant products)
63and/or, in the absence of the expected UV-induced immu-
64nosuppression, sensitization to a new epidermal autoantigen
65has occurred (Hawk 2004; Be´ani 2009).
66When considering only phototoxic and photoallergic
67dermatitis there is also an overlap between these two
68reaction patterns. Except for a few chemicals, as piroxicam
69and olaquindox, which do not have an intrinsic photo-
70toxic potential and induce only photoallergic reactions
71(Figueiredo 1994), most substances can induce both
72photoallergic and phototoxic reaction. For instance,
73potent phototoxic agents like psoralens can induce
74photoallergy in some individuals. There is also some over-
75lap between phototoxicity and photoallergy in the clinical
76characteristics of the reaction and their time course.
77Most phototoxic reactions are well recognized, are not
78severe, and do not call medical attention. Others may be
79severe and are often misdiagnosed, as their relation to sun
80exposure is not so obvious, namely, the recently described
81UV-induced skin cancers in patients on voriconazole
82(McCarthy et al. 2007; Cowen et al. 2010).
83Photosensitivity from exogenous agents is now con-
84sidered rare (Darvay et al. 2001; Bryden et al. 2006), but it
85may be underreported or underdiagnosed (Zeeli et al.
862006). Many photosensitizers have been recognized and
87removed from the market (salicylanilides, PABA) or sun
88avoidance is recommended when they are used
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89 (lomefloxacin). Also, there is an increasing concern on
90 premarketing studies on the photosensitizing potential
91 of chemicals for human use. Nevertheless, photosensitiv-
92 ity is still a field on intense research. New photosensitizers
93 are discovered, either causing skin disease (Chang et al.
94 2009) or for therapeutic purposes. Also, new mechanisms
95 underlying the photosensitizing potential of chemicals
96 and new aspects of clinical presentation of photosensitiv-
97 ity are recognized, which may be important to understand
98 diseases that course with photosensitivity, as HIV infec-
99 tion (Be´ani 2009).
100 2 General Mechanisms of
101 Phototoxicity from Exogenous
102
Chemicals
103 Normal skin is prepared to live with sunlight and takes
104 benefit from it. Skin chromophores are activated upon sun
105 exposure and undergo chemical reactions which are
106 important for survival under the sun and necessary for
107 human life: 7-dehydrocholesterol is activated by UVB to
108 form pro-vitamin D3 and Vitamin D.
109 Photosensitivity develops when an abnormal chromo-
110 phore is present in the skin or when a normal chromo-
111 phore in present in exaggerated amounts. When excited by
112 a photon these molecules receiving the energy suffer
113 changes within the molecule itself, often also within
114 neighboring molecules, in a cascade of events that result
115 in skin damage and inflammation. The energy received by
116 the molecule excites the electrons in the outer orbits; the
117 molecule becomes reactive and can undergo several types
118 of modifications within itself (isomerization, breaking of
119 double bounds, oxidation) or react with neighboring mol-
120 ecules, eventually forming free radicals or reactive oxygen
121 species (ROS). These ROS and other free radicals damage
122 cellular organelles by modifying unsaturated lipids of cell
123 membranes, aromatic amino acids of proteins, and pyrim-
124 idine bases of DNA or RNA. If the repair mechanisms do
125 not act immediately, there is damage of these cellular
126 structures and suffering or death of skin cells. In this
127 process, inflammatory mediators are generated (prosta-
128 glandins, leukotrienes, IL-1, 6, 8, other cytokines and
129 chemokines) with consequent visible skin lesions – this
130 is briefly the mechanism of phototoxicity (Hawk 1999;
131 Ferguson 1999). In photoallergy, the energy of the photon
132 transforms the chromophore into a photoproduct or
133 enhances its reactionwith an endogenous peptide forming
134 a hapten or an allergen that is specifically recognized by
135 the immune system.
136Several phototoxic substances, like psoralens, chlor-
137promazine, and fluorquinolones, apart from the capacity
138to generate free radicals and cell death responsible for
139acute phototoxicity, also enhance chromosomal damage
140in the presence of UVR, both in vitro and in vivo (Seto
141et al. 2010). Therefore, they are photogenotoxic and
142photomutagenic, which is usually associated with
143photoimmunosupression, and have consequent implica-
144tions in animal photocarcinogenesis (Klecak et al. 1997;
145Marrot et al. 2003; Lhiaubet-Vallet et al. 2009; Mu¨ller et al.
1461998). Epidemiological studies and recent reports also
147show enhancement of photocarcinogenesis in humans
148exposed to photoactive chemicals (Cowen et al. 2010;
149Placzek et al. 1999; Miller et al. 2010).
150From the solar spectrum that reaches the earth, UV
151radiation, and particularly UVA (320–400 nm), is respon-
152sible for most cases of photosensitivity. Even though
153some chromophores absorb in the UVB (290–320 nm)
154and UVB is more energetic, UVA penetrates the skin more
155deeply and, particularly for systemic chromophores, this is
156certainly the most important spectrum for inducing
157photodermatosis (Hawk 1999). Only exceptional cases
158have a well-documented exogenous photosensitivity
159exclusively from UVB (Fujimoto et al. 2009).
160
2.1 Phototoxicity Versus Phototoallergy
161In theory, it is easy to differentiate photoallergy from
162phototoxicity, but there are many overlapping aspects, as
163presented below.
164Classically, photoallergy develops only in a limited
165number in individuals, needs previous sensitization but
166occurs also with cross-reactive chemicals, is not dose-
167dependent, develops on low UV dose, appears as eczema
168that can spread to nonexposed sites and, on skin biopsy,
169there is mainly T-cell infiltration, spongiosis, and vesicles.
170Phototoxicity is more frequent, develops in every individ-
171ual, as long as enough photosensitizer and sun exposure
172are present, occurs on a first and single contact, with no
173flare-ups or cross-reactions, appears mainly as well-
174demarcated erythema exclusively on sun-exposed areas
175(mimicking sunburn), resolves with hyperpigmentation
176and, on histology, apoptotic keratinocytes (sunburn
177cells) are abundant (> Table 18.1).
178These are the two polar aspects of photosensitivity,
179but, as referred previously, some molecules may induce
180both phototoxic and photoallergic reactions and, in the
181same patient, aspects that resemble phototoxicity may
182coexist with others that suggest photoallergy.
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183 After contact with plant furocoumarins (Ruta
184 graveolens, Ficus carica, Umbelliferae) or during photoche-
185 motherapy, some individuals can become reactive to very
186 low concentrations of psoralens (Karimian-Teherani et al.
187 2008) and with phototoxic drugs like promethazine and
188 lomefloxacin, patients may develop photoallergy, reacting
189 to very low doses of the drug or sun exposure (Gonc¸alo
190 1998; Oliveira et al. 1996; Kurumajin and Shono 1992).
191 Very probably, as for contact allergens that have an inher-
192 ent ‘‘irritant’’ potential to awaken the innate immune
193 system promoting sensitization (Neves et al. 2008),
194 photoallergens are photoactive molecules with some
195 inherent phototoxicity. This innate inflammatory reaction
196 can work as the ‘‘danger signal’’ necessary to initiate the
197 sensitizing process.
198 Although phototoxicity can occur on a first contact
199 and photoallergy needs previous sensitization, individuals
200 previously sensitized by contact or photocontact to
201 a similar molecule can react on a first exposure. This
202 occurs in individuals with contact allergy to thimerosalAu3
203 and its moiety thiosalicylic acid who develop photoallergy
204 to piroxicam on the first drug intake and patients allergic
205 to perfumes (cinnamic alcohol) who may have
206 photoallergic contact dermatitis from ketoprofen on
207 a first exposure (Foti et al. 2008). Upon UVA irradiation,
208piroxicam is photodecomposed into a molecule very sim-
209ilar antigenically and structurally to thiosalicylic
210acid (Gonc¸alo et al. 1992; Hariva et al. 1993) and there
211are conformational similarities between cinnamate
212derivatives and ketoprofen photoproducts (Foti et al.
2132008; Pigatto et al. 1996)
214Phototoxicity is considered to occur in every patient as
215long as enough chromophore and sun are present at the
216same time, but even in drug phototoxicity and phytopho-
217todermatitis there is some individual susceptibility, even
218though the parameters that characterize this susceptibility
219are not precisely known.




223As referred, clinical and evolutive aspects suggesting of
224a phototoxic dermatitis from exogenous chemicals can
225coexist with signs of photoallergy or other photo-immune
226reactions; therefore, in most instances it is best to call
227photosensitivity. Nevertheless, in this chapter, clinical pat-
228terns that are more suggestive of phototoxicity will be
229described.
230The clinical patterns of phototosensitivity from exog-
231enous chemicals vary from urticaria through eczema or
232subacute lupus erythematosus up to vitiligo-like lesions or
233squamous cell carcinomas (Gonc¸alo 1998; Ferguson 1999;
234McCarthy et al. 2007). They can very typical, like
235phytophotodermatitis or acute exaggerated sunburn
236from a phototoxic drug, but sometimes, the diagnosis or
237even the suspicion of photosensitivity is not so obvious. It
238is the example of cases involving nonexposed areas, which
239occurs mainly in photoallergy, or when there is no imme-
240diate or evident relation with exposure to the sun and
241exogenous chemicals, as in actinic keratosis and skin can-
242cer in patients chronically exposed to photoactive drugs
243(> Table 18.2).
244Skin reactions can occur immediately after sun expo-
245sure, as in photocontact urticaria, but the appearance of
246skin lesions may be delayed 1 or 2 days, as in most photo-
247toxic or photoallergic contact dermatitis or systemic
248photoallergy, several days or weeks, as in pseudoporphyria
249or subacute lupus erythematosus, or even years, in
250photocarcinogenesis enhanced by a long exposure to the
251sun and the photoactive chemicals.
252Localization of the lesions depends on whether the
253photoactive chemical is applied on the skin (photocontact
254dermatitis) or the photosensitizer is a systemic drug. In
t1:1
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255 photocontact dermatitis from a topical agent, dermatitis
256 draws the area of application and concomitant sun
257 exposure, but distant lesions can occur in areas of acci-
258 dental contact, as in a contralateral limb (kissing faces of
259 the legs) or in areas of inadvertent spread by the hands
260 or contaminated objects (Hindse´n et al. 2004). Some
261topical drugs, as nonsteroidal anti-inflammatory drugs
262(NSAIDs), are considerably absorbed through the skin
263and lesional distribution can be similar to systemic
264photosensitivity.
265In systemic photosensitivity the reaction usually
266involves, in a symmetric distribution, all exposed areas of
267the face, the V-shaped area of the neck and upper chest,
268dorsum of the hands and forearms, while shaded areas are
269spared. This corresponds, in the face, to the upper eyelids,
270upper lip, deepwrinkles (> Fig. 18.1), retroauricular areas,
271submandibular area, and areas covered by the beard or
272hair. Large body folds, like the axillae, groins, finger webs,
273and areas covered by clothing or other accessories (watch
274strip, shoes) (> Fig. 18.2) are also usually spared. Involve-
275ment of these shaded areas suggests dermatitis from an
276airborne allergen or irritant.
277In exceptional cases where sun exposure is asymmetric,
278this pattern can be different, as in car drivers who only
279expose the left arm. Sometimes, in systemic photosensitiv-
280ity, the lower lip is mainly or almost exclusively involved,
281because of its higher exposure and, very probably, because
282of the thinner corneal layer more prone to phototoxic





















Acute phototoxicity from amiodarone, mimicking sunburn
and sparing the deep wrinkles
t2:1
. Table 18.2
Clinical patterns of photosensitivity
Predominant in phototoxicity In photoallergy
t2:2
Exaggerated ‘‘sunburn’’ Urticaria in sun-exposed
area
t2:3






































Photosensitivity from systemic lomefloxacin, sparing
the sunshaded areas and the wrist protected from
the watch
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284
3.1 Acute Patterns of Phototoxicity
285 3.1.1 Immediate Reactions
286 Apart from idiopathic solar urticaria, for which
287 a chromophore is not identified, immune or nonimmune
288 urticaria as a manifestation of photosensitivity from
289 an exogenous substance has been rarely described with
290 5-aminolevulinic acid, used in photodynamic therapy
291 (Kerr et al. 2007), with oxybenzone in sunscreens (Collins
292 and Ferguson 1994) and chlorpromazine (Lovell et al.
293 1986). Nevertheless for some drugs, like amiodarone and
294 benoxaprofen (already removed from the market), imme-
295 diate prickling and burning with transient erythema may
296 occur as a manifestation of photosensitivity (Ferguson
297 1999).
298 3.1.2 Acute Phototoxic Dermatitis,
299 Mimicking Sunburn
300 The main clinical pattern of acute phototoxicity, mimick-
301 ing exaggerated sunburn develops within 12–24 h of sun
302 exposure. It consists on a well-demarcated erythema with
303 prickling and burning, eventually with skin pain but typ-
304 ically without pruritus. Erythema can progress to vesicles
305 and bullae, but eczematous lesions with small vesicles or
306 multiforme-like lesions involving also covered areas is not
307 usual in phototoxicity and recalls mainly photoallergy.
308 Like in exaggerated sunburn, acute phototoxicity pro-
309 gresses to large sheets of epidermal detachment within the
310 next days and resolves with residual hyperpigmentation.
311 In this pattern of phototoxicity, there is typically a very
312 sharp limit between affected and nonaffected shaded area
313 (> Fig. 18.2).
314
3.2 Subacute Patterns of Phototoxicity
315 Some clinical patterns of photosensitivity develop within
316 days or weeks after exposure to the photosensitizer and the
317 sun. These patterns that evoke mainly a phototoxic reac-
318 tion are pseudoporphyria, photoonycholsys, hyper or
319 hypopigmentation, telangiectasia, and purpura.
320 3.2.1 Pseudoporphyria
321 Pseudoporphyria presents as chronic skin fragility with
322 flaccid bullae on non-inflamed exposed skin, occasionally
323 with later milia formation, that resembles porphyria
324cutanea tarda both clinically and on histopathology (bul-
325lae formation below the lamina densa). It occurs in indi-
326viduals with no inborn error in porphyrinmetabolism and
327no increase of endogenous porphyrins.
328It was observed in individuals regularly exposed
329to solarium (Kochs et al. 2009) or to some systemic
330drugs. Nalidixic acid, furosemide, and naproxen pre-
331dominantly in children (Ferguson 1999; Figueiredo
3321994) were initially described as causing pseudoporphyria
333but, more recently, many others drugs are associated with
334this phototoxic reaction: ciprofloxacin (Schmutz et al.
3352008), celecoxib (Cummins et al. 2000; Schmutz et al.
3362006), voriconazole (Auffret et al. 2006), torasemide
337(Pe´rez-Bustillo et al. 2008), and imatinib (Timmer-de
338Mik et al. 2009). This represents a typical phototoxic
339reaction where the drug, as the uroporphyrin in the
340hereditary disease, probably induces phototoxicity
341through singlet oxygen (Ferguson 1999; Figueiredo 1994).
3423.2.2 Photoonycholysis
343Photoonycholysis, with a half-moon distal onycholysis of
344one or several nails, is a typical pattern of phototoxicity,
345occurring most often as the single manifestation of pho-
346totoxicity (> Fig. 18.3). It appears late (2–3 weeks after
347drug intake and sun exposure), sometimes preceded by
348pain in the nail apparatus. It occurs mainly with tetracy-
349clines (demethylchlortetracycline or doxycycline) (Passier
350et al. 2004), psoralens, and fluorquinolones (Baran and
351Juhlin 2002). There is no definite explanation for the
352single involvement of the nail: The nail bed is relatively
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354 nail plate may work as a lens, and the inflammatory
355 reaction induces detachment of the nail plate from the
356 nail bed (Passier et al. 2004; Baran and Juhlin 2002;
357 Gregoriou et al. 2008).
358 3.2.3 Dyschromia
359 Hyperpigmentation that follows mainly an acute
360 phototoxic reaction is frequently due to the residual
361 melanocytic hyperpigmentation, and is very typical in
362 phytophotodermatitis (> Fig. 18.3).
363 In rare occasions, like in flutamide-induced photosen-
364 sitivity, vitiliginous lesions with sharp limits occur after the
365 acute reaction (Gonc¸alo et al. 1999; Vilaplana et al. 1990).
366 Dyschromia from the accumulation of the photoactive
367 drug or its metabolites in the dermis occurs in a smaller
368 percentage of patients after acute phototoxicity from
369 amiodarone, minocycline, or phenothiazines (Ammoury
370 et al. 2008; Vassileva et al. 1998). Some patients with lower
371 phototypes also develop a golden-brown, slate gray, or
372 bluish color on sun-exposed areas, that persists much
373 longer than residual melanocytic hyperpigmentation
374 (Ferguson 1999; Ammoury et al. 2008).
375 3.2.4 Other Clinical Patterns
376 Telangiectasia as a manifestation of photosensitivity has
377 been reported with calcium channel blockers (Ferguson
378 1999) and the telangiectatic pattern of photoaging with
379 lesions mainly in the lateral folds of the neck, sparing the
380 shaded skin under the chin, is frequently observed in
381 patients chronically exposed to the sun or to photoactive
382 drugs. In rare cases, petechial purpurawith sharp limits on
383 the transition to the shaded areas was described with
384 ciprofloxacin (Urbina et al. 2006).
385 Pellagra is associated with the prolonged use of isoni-
386 azid, that consumes niacin for its metabolization, and
387 pellagroid reactions were reported with the anticancer
388 agents, like 6-mercaptopurine and 5-fluorouracil.
389 3.3 Delayed and Late Effects of
390
Phototoxicity
391 Patients that are chronically exposed to photoactive
392 drugs may develop other patterns of skin lesions, like
393chronic actinic dermatitis and lupus erythematosus
394where autoimmune reactions are predominantly
395involved, or accelerated photoaging and skin cancers,
396that are explained by the photogenotoxic effect of some
397phototoxic molecules.
398There is a consensual agreement on the increased risk
399of skin cancers after longtime therapeutic exposure to
400PUVA phototherapy (Ferguson 1999) but, apart from
401psoralens, other drugs like naproxen, chlorpromazine,
402and the fluorquinolones, particularly lomefloxacin, also
403augment in vitro UV-induced DNA aggression and
404increase epidermal neoplasia in animals (Klecak et al.
4051997). Recent reports and epidemiological data also cor-
406relate chronic human exposure to photoactive drugs with
407an increased risk of developing actinic keratoses,
408nonmelanoma skin cancer and, even, malignant mela-
409noma (Placzek et al. 1999; McCarthy et al. 2007; Jensen
410et al. 2008). In 1999, the group of Przybilla showed an
411association between actinic keratosis and the use of poten-
412tially photosensitizing chemicals (Placzek et al. 1999).
413More recent studies tend to confirm an increased risk for
414skin cancer in patients chronically exposed to psoralens,
415fluoroquinolones, and diuretics (Jensen et al. 2008) and
416voriconazole (McCarthy et al. 2007; Cowen et al. 2010;
417Miller et al. 2010). Also, patients with severe chronic
418photosensitivity may develop skin cancers in the
419photoexposed areas, like squamous cell carcinoma with
420ciprofloxacin (personal experience) and both squamous
421cell carcinoma and melanoma with voriconazole (Cowen
422et al. 2010; Miller et al. 2010).
423Also the photoaging process may be enhanced by the
424exposure to topical or systemic photosensitizers.
425
4 Main Sources of UV Exposure
426The sun is the main source of UV exposure even in the
427occupational setting. Farmers, gardeners, construction
428workers, fishermen, sailors, policemen, ski instructors, oil-
429field workers, and road workers are occupations where sun
430exposure can be heavy, prolonged, and begin at an early age.
431Artificial sources of UVexposure are present in several
432occupational settings and, even though protective mea-
433sures and instructions for UV avoidance are active, UV
434exposure can be relevant in some of them. Some examples
435are the rooms for solarium and phototherapy, plants for
436UV curing of printing inks, lacquers, dental acrilates, or
437nail modeling acrilates, indoor working places artificially
438illuminated with UVA light sources with no plastic/glass
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439 cover, and areas of food cooking where insect traps have
440 UVA emission to attract the insects.
441 The highest artificial UVexposure in occupational set-
442 ting occurs in welders, particularly in electric arc welding.
443 These individuals may suffer UV-induced erythema, burns,
444 and keratitis (welder’s flash) during inadvertent exposure
445 during the arc welding process (Hawk 1999).
446 Exposure to the more energetic UVC rays
447 (260–265 nm) can also occur in processes of sterilization
448 or disinfection of drinking water or water for the cosmetic
449 or pharmaceutical industry and swimming pools, to
450 treat sewage effluents and to sterilize the air in some
451 cabinets, research laboratories, and operating theaters
452 (Hawk 1999).
453 5 Main Topical and Systemic
454
Photosensitizers
455 There is a large and increasing list of photoactive mole-
456 cules to which we can be exposed to in our daily life and
457 that can induce photosensitivity (> Table 18.3). But there
458 has been a higher concern on the evaluation of the pho-
459 totoxic potential of cosmetics and consumer products
460 before marketing and many photosensitizers have been
461 removed or highly reduced in our ambience.
462 These ‘‘historical’’ photosensitizers include some
463 predominantly photoallergic others mainly phototoxic:
464 musk ambrette and natural bergamot oil were removed by
465 the perfume industry, the sunscreen isopropyl–
466 dibenzoylmethane was withdrawn in 1994, the sunscreen
467 PABA (para-aminobenzoic acid) which sensitized about
468 4% of the American population in the 1950s is no longer
469 used (Lowe 2006), the antibiotic olaquindox, a swine feed
470 additive, was banned in 1998 by the European Commission
471 (Emmert et al. 2007), and the halogenated salicylanylides
472 were removed from disinfectants and hygiene products in
473 most countries, since 1976. Nevertheless, even though
474 some products are not available in Europe, they can be
475 ‘‘imported’’ from other countries and induce photosensi-
476 tivity (Emmert et al. 2007; Waters et al. 2009).
477 In most reports from Europe and the USA, the main
478 topical photosensitizers are the UV filters (Darvay et al.
479 2001; Sheuer and Warshaw 2006) which represent
480 5.6Au4 –80% of the cases diagnosed by photopatch testing
481 (Darvay et al. 2001; Cardoso et al. 2009; Bakkum and
482 Heule 2002; Leonard et al. 2005), but they represent
483 photoallergic reactions in the vast majority of cases.
484 Furocoumarin-rich plants are an important source of
t3:1
. Table 18.3





Umbelliferae: Ammi majus; Apium
graveolens (celery);
t3:3






Rutacea: Citrus spp, Citrus aurantica v.
bergamia (bergamot)
t3:6
Citrus aurantifolia (lime); Citrus limon
(lemon)
t3:7
Ruta graveolans (common rue);
Dictamus albus (burning bush)
t3:8



















































Phototoxic Dermatitis 18 7
Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD
Page Number: 0 Date:1/11/11 Time:12:55:46
485 phototoxicity, mainly in more sunny countries, and drugs,
486 both phototoxic and photoallergic are, by far, the most
487 frequent photosensitizers in Southern Europe (Cardoso
488 et al. 2009; La Cuadra-Oyanguren et al. 2007; Leonard
489 et al. 2005; Pigatto et al. 2008)
490
5.1 UV Filters
491 Due to the increased awareness of the sun-damaging
492 effects, sunscreens are widely used, and UV filters are
493 also included in moisturizing and facial creams, lipstick,
494 nail varnish, shampoos, and other hair products, but
495 adverse skin reactions from UV filters are not reported
496 proportionally (Darvay et al. 2001). Also, as referred, most
497 represent allergic, photoallergic, or photoaggravated aller-
498 gic contact dermatitis, not phototoxicity (Bryden et al.
499 2006; Berne and Ros 1998; Pigatto et al. 2008; Leonard
500 et al. 2005; La Cuadra-Oyanguren et al. 2007; Cardoso
501 et al. 2009).
502 The newer UV filters – Mexoryl SX (terephtalydene
503 dicamphor sulfonic acid), Tinosorb M (methylene-bis-
504 benzotriazolyl tetramethylbutylphenol or bisoctrizole),
505 and Tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl
506 triazine) – are photostable molecules and, in mixtures of
507 several sunscreens, are able to photostabilize older
508 photolabile UV filters, like butyl-
509 methoxydibenzoylmethane and cinnamates. Therefore,
510 they seem to be more efficient in protecting from the
511 harmful effects of UVR (Lowe 2006) and, eventually, in
512 reducing photosensitivity from the other UV filters.
513
5.2 Plants Causing Phytophotodermatitis
514 Photoactive furocoumarins, e.g., bergapten (5- methoxy-
515 psoralen), 8-methoxypsoralen, 5,6 dimethoxyisopsoralen,
516sphondin (6-methoxyisopsoralen), and isobergapten
517(5-methoxyisopsoralen) run in the sap of several plants,
518in variable amounts. They are beneficial for the
519plant which uses them as a protection against fungus
520and insects.
521Since the antiquity, these substances have been used in
522folk medicine in the treatment of vitiligo and, more
523recently, in photochemotherapy (PUVA), but their acute
524and chronic phototoxic potential is well known and mea-
525sures are regularly considered to avoid these adverse
526effects: A low UV dose is used in the beginning of therapy
527and in patients with lower phototypes, children under 16
528are not usually admitted on PUVA therapy, and
529a cumulative dose below 1,000–1,500 J/cm2 of UVA is
530advised for patients on photochemotherapy to reduce
531the potential risk of photocarcinogenesis and photoaging.
532Aromatic oils rich in furocoumarins were used by the
533cosmetic industry in tanning oils, but their use has
534been considerably reduced as this accelerated tanning
535is harmful – the photosensitizer in the oil enhances
536UV-induced DNA aggression.
537The natural bergamot oil, extracted from the rind of
538Citrus bergamia, previously included in oils and perfumes,
539was responsible for a very particular type of phototoxic
540dermatitis, ‘‘breloque dermatitis,’’ or berlock dermatitis. It
541presented as erythema followed by hyperpigmentation, in
542a very particular shape of a pendant-like figure simulating
543a breloque, beginning in the face or neck and descending
544down to the collar. It corresponded to the place where the
545first drop of perfume is applied and the adjacent and
546dependent draining area. The natural oil of bergamot is
547no more used in perfumes and breloque dermatitis is an
548image of the past, but citrus oils containing psoralens can
549still induce phototoxicity when used in aromatic oils in
550sauna or in massages (Lovell 2000).
551Nowadays, phototoxic dermatitis from psoralens
552occurs mainly from inadvertent contact with plants, either
553during recreation or in occupational settings. Main occu-
554pational exposures occur in rural workers or gardeners
555who harvest fruits or vegetables (parsnip, figs) or cut
556bushes and weeds (common rue – Ruta graveolens, burn-
557ing bush – Dictamnus albus, or fig trees – Ficus carica)
558(Gonc¸alo et al. 1989; Lovell 2000) and in barmen who
559squeeze and peal the lime (Citrus aurantifolia) and other
560citrus fruits to prepare cocktails in the sunny weather
561(Wagner et al. 2002; Gonc¸alo 2004; Lovell 2000)
562(> Fig. 18.4).
563The most typical pattern of phytophotodermatitis was
564described by Oppenheim in 1934 – dermatosis bullosa
565striata pratensis. Corresponding to the contact with the
566damaged leaves of the plant, prickling linear erythematous
. Table 18.3 (Continued)
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567 skin streaks develop within 24–48 h followed by painful
568 vesicles and bullae (> Figs. 18.5 and > 18.6). This
569 gradually gives rise to long-lasting typical browny linear
570 hyperpigmentation which, sometimes, allows a retrospec-
571 tive diagnosis (Gonc¸alo 2004).
572 Other patterns of phytophotodermatitis are the
573 ‘‘strimmer dermatitis,’’ a more diffuse involvement as the
574 sap of the plant is sprayed all over the body by the string
575 trimmer (Lovell 2000), a leg dermatitis in walkers who
576 develop lesions only above the socks, and skin lesions in
577 children who make trumpets or pea shooters from the
578hollow stems of the giant hogweed (Heracleum
579mantegazzianum) and developed blisters around their
580mouth (Lovell 2000).
581Very occasionally, the ingestion of these plants can
582induce a systemic photosensitivity as in the cases of celery,
583parsnip or infusions of St. John’s wort (Hypericum
584perforatum L.) used to treat depression (Lovell 2000).
585Also, they are occasionally used topic drug as a ‘‘folk
586medicine’’ with impressive adverse effects, as in a recent
587report where an infusion of Ruta graveolens was applied
588topically to relieve pain in fibromyalgia (Arias-Santiago
589et al. 2009).
590Plants rich in furocoumarins causing phytophoto-
591dermatitis occur all over the globe and belong mainly to




595Drugs used systemically or applied topically are the main
596cause of exogenous photosensitivity, particularly in
597Southern European countries (Cardoso et al. 2009; La
598Cuadra-Oyanguren et al. 2007; Leonard et al. 2005;
599Pigatto et al. 2008).
600Drugs manipulated in an occupational setting can
601induce photosensitivity: carprofen, a NSAID no more
602used in humans, induced photoallergic contact dermatitis
603in workers who manufacture the drug for animals (Kerr
604et al. Au52008; Walker et al. 2006), and photosensitivity has
605been reported in nurses and family members who
606smashed the tablets of chlorpromazine to give to their





















Residual pigmentation in the forearms in a barman who
squeezed limes and lemons for cocktails, during an outdoor





















Phytophotodermatitis with linear streaks of erythema and
hyperpigmentation in a patient who contacted Ruta





















Phytophotodermatitis with linear bullous lesions in the
arms, after cutting a fig tree during a sunny day
Phototoxic Dermatitis 18 9
Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD
Page Number: 0 Date:1/11/11 Time:12:55:49
608 The main systemic drugs inducing photosensitivity are
609 antimicrobials, particularly tetracyclines, fluorquinolones,
610 sulfonamides, and some antifungals, NSAIDs, phenothia-
611 zines, and cardiovascular drugs. After topical application,
612 NSAIDs are by far the most frequent cause (Cardoso et al.
613 2009; La Cuadra-Oyanguren et al. 2007; Leonard et al.
614 2005; Pigatto et al. 2008).
615 5.3.1 Antimicrobials
616 Systemic tetracyclines, particularly doxycycline and
617 minocycline, are highly phototoxic, induce photoony-
618 cholysis and pseudoporphyria and, the latter, can also
619 induce a bluish persistent pigmentation (Vassileva et al.
620 1998; Ferguson 1999).
621 The fluorquinolones induce phototoxic reactions, in
622 some cases presenting as pseudoporphyria (Schmutz et al.
623 2008), as initially described for the first quinolone antibi-
624 otic, nalidixic acid (Vassileva et al. 1998). Ciprofloxacin
625 was also responsible for purpura in photo-exposed areas
626 (Urbina et al. 2006). Phototoxicity is particularly impor-
627 tant and frequent (4–15% of treated patients) with
628 fleroxacin, lomefloxacin, sparfloxacin, pefloxacin, and
629 less frequent with ciprofloxacin, norfloxacin, ofloxacin,
630 and enoxacin (Ferguson 1999). The recommendation to
631 take the drug by the end of the day, therefore reducing
632 drug concentrations in the circulation and in the skin
633 during midday, can reduce this phototoxic reaction.
634 Although in vitroAu6 and in vivo tests prove the high
635 phototoxic potential of fluorquinolones, photoallergy
636 has also been reported with lomefloxacin (Oliveira et al.
637 1996; Kurumajin and Shono 1992) and enoxacin
638 (Vassileva et al. 1998), sometimes with cross-reaction to
639 other fluorquinolones (ciprofloxacin and flerofloxacin)
640 (Kimura and Kawada 1998; Correia et al. 1994), positive
641 lymphocyte stimulation tests, and drug-specific Th1 cells
642 that recognize skin cells combined with UV irradiated
643 fluorquinolone (Tokura et al. 2001). Moreover, the
644 fluorquinolones also photosensitize DNA and may be
645 photomutagenic and photocarcinogenic (Klecak et al.
646 1997). A patient on long-term ciprofloxacin therapy for
647 multiresistant tuberculosis developed photosensitivity
648 and highly aggressive squamous cell carcinomas of the
649 face (personal experience).
650 Sulfonamide antibacterials, as well as sulfa-drug ana-
651 logs (thiazide diuretics, hypoglycemic sulfonylureas, and
652 celecoxib) and dapsone (diaminodiphenylsulfone) have
653 been reported to cause photosensitivity within the spec-
654 trum both of UVB and UVA (Vassileva et al. 1998; Yazici
655 et al. 2004) but this side effect is not so frequent with
656cotrimoxazole (trimethoprim/sulfamethoxazole)
657(Vassileva et al. 1998; Ferguson 1999).
658Grisefulvin is a known phototoxic drug and can aggra-
659vate lupus erythematosus, as the more recent antifungal,
660terbinafine, which also induced subacute lupus
661erythematosus in patients with anti-Ro antibodies (Farhi
662et al. 2006). Another antifungal from a different chemical
663group, voriconazole, has recently been reported to cause
664severe photosensitivity (Be´ani 2009; Frick et al. 2010) and
665was considered responsible for skin cancer, including
666malignant melanoma (Auffret et al. 2006; McCarthy
667et al. 2007; Cowen et al. 2010; Miller et al. 2010).
6685.3.2 Nonsteroidal Anti-inflammatory
669Drugs
670Benoxaprofen marketed between 1980 and 1982 called the
671attention to photosensitivity from this class of drugs.
672Thereafter, photosensitivity was reported with all the
673other arylpropionic derivatives (carprofen, naproxen,
674suprofen, tiaprofenic acid, ketoprofen, and ibuprofen)
675and NSAIDs from other groups (azapropazone, diclofenac,
676piroxicam, fenilbutazone, celecoxib, benzydamine, and
677etofenamate) (Figueiredo 1994). The in vitro and in vivo
678phototoxic potential has been documented particularly
679for tiaprofenic acid (Figueiredo 1994). In humans,
680photopatch testing showed typically phototoxic reactions
681in more than half patients tested with tiaprofenic acid
682(5% pet) and 5 J/cm2 of UVA (Gonc¸alo and Figueiredo
6831992; Neumann et al. 1994, 2000), but in other studies
684tiaprofenic acid was typically photoallergic (Pigatto et al.
6851996; LeCoz et al. 1998; Foti et al. 2008), therefore calling
686the attention to the concomitancy of both patterns of
687photosensitivity with the same drug.
688Most topically appliedNSAIDs are absorbed through the
689skin and cause distant lesions, resembling systemic photo-
690sensitivity. Benzydamine, widely used in the oral or genital
691mucosa, causes photosensitivity at distant sites (Elgezua et al.
6922004), eventually after systemic absorption (Cardoso et al.
6932009; La Cuadra-Oyanguren et al. 2007) and, when used in
694the mouth, can induce cheilitis and chin dermatitis as
695a manifestation of photoallergy (Cardoso et al. 2009).
696Although ketoprofen and piroxicam are not the most
697sold NSAIDs, they cause most cases of photosensitivity
698(Cardoso et al. 2009; La Cuadra-Oyanguren et al. 2007;
699Leonard et al. 2005), particularly photoallergy and with
700a peculiar pattern of cross-reactions (Imai et al. 2005)
701(Be´ani 2009; Cardoso et al. 2009): cinnamic alcohol and
702aldehyde, oxybenzone, octocrylene, and fenofibrate for
703ketoprofene (Pigatto et al. 1996; LeCoz et al. 1998;
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704 Devleeschouwer et al. 2008; Foti et al. 2008), and thimer-
705 osal and thiosalicylic acid for piroxicam (Gonc¸alo et al.
706 1992; Hariva et al. 1993).
707 5.3.3 Other Drugs as Photosensitizers
708 Phenothiazines used systemically (chlorpromazine and
709 thioridazine) can induce photosensitivity, often with
710 a lichenoid pattern and with residual pigmentation
711 (Ferguson 1999). They are typically phototoxic, both in
712 vitro and in vivo, but some cases of photoallergy also
713 occur (Cardoso et al. 2009). Promethazine is a highly
714 phototoxic drug that is still used as a topical antipruritic,
715 at least in Portugal and Greece. In this setting, it induces
716 many cases of photosensitivity, many of them
717 photoallergic (Cardoso et al. 2009; Katsarou et al. 2008).
718 Its analogue, chlorproethazine, marketed in France as
719 Neuriplege® cream for muscle pain (Genevrier, Antibes,
720 France), is also a frequent cause of photoallergic contact
721 dermatitis (Barbaud et al.Au7 2001; Kerr et al. 2008).
722 The antiarrhythmic amiodarone is a well-known pho-
723 tosensitizer that is still widely used. Apart from erythema
724 in sun-exposed areas, it induces a bluish-gray hyperpig-
725 mentation in sun-exposed areas due to the accumulation
726 of drug metabolites in the dermis (Ammoury et al. 2008).
727 The list of drugs causing photosensitivity is very large
728 and always increasing, with the recent inclusion of biologics,
729 namely, vandetanib, an orally effective VEGF-inhibitor used
730 in oncology (Chang et al. 2009). Therefore, whenever
731 a patient has a photosensitive eruption a systematic
732 inquiry for drugs should be carefully conducted.
733 6 Diagnostic Procedures in
734
Photosensitivity
735 Sometimes the lesions are so typical for a dermatologist, as
736 in phytophotodermatitis or in exaggerated sunburn after
737 the use of a systemic phototoxic drug, that no further
738 diagnostic procedures are needed. A simple questionnaire
739 can find the responsible agent. Also, in typical phototoxic
740 reactions, both photopatch and photoprovocation tests
741 are positive in the great majority of tested individuals.
742 Therefore, they are not particularly useful for confirming
743 the etiology of a phototoxic reaction, but they can disclose
744 a hidden photoallergy.
745 Photopatch testing should be performed according to
746 a standardized procedure (Bruynzeel et al. 2004), using
747 a photoallergen series adapted to the geographic area
748 (Cardoso et al. 2009; Gonc¸alo 2010) with additions
749according to patient exposure. Irradiation of one set of
750allergens at day 1 or day 2 with 5 J/cm2 of UVA is advised
751and readings should be performed immediately after
752irradiation and also 48 and/or 72 h thereafter (Bruynzeel
753et al. 2004).
754Photopatch tests results have to be carefully
755interpreted. A reaction only in the irradiated side mainly
756with erythema and edema, without pruritus, exclusively
757limited to the test chamber area, with very sharp limits
758that begins shortly after irradiation, has its highest inten-
759sity by 24 h and regress by 48/72 h (decrescendo reaction)
760with hyperpigmentation, suggests a phototoxic reaction.
761A similar reaction may be observed in many individuals
762tested in the same conditions and, if histology is
763performed, there are many sunburn cells in the epidermis.
764On the other hand, a pruritic erythema with vesicles,
765diffuse limits extending beyond the chamber limit, that
766increases in intensity until 48–72 h after UV irradiation
767(crescendo reaction), suggests photoallergy (Neumann
768et al. 1994). But sometimes the photopatch test pattern
769is not so typical and the difficulties previously referred in
770the interpretation of clinical cases also occur in the inter-
771pretation of the photopatch tests.
772The main indication for photopatch testing is the
773diagnosis of photallergic contact dermatitis, but photopatch
774testing can also be useful in the study of systemic drug
775photosensitivity (Gonc¸alo 1998, 2010; Barbaud et al. 2001).
776
7 Conclusions
777Phototoxic, photoallergic, and overlapping photosensitive
778reactions are still a frequent problem. They have a highly
779polymorphic clinical presentation, with different time
780courses and variations in the responsible agents depending
781on geographic areas and over times. Therefore, the der-
782matologist must be highly alert to search for a possible
783involvement of an exogenous chromophore in
784a photosensitive patient and try to confirm its contribu-
785tion to photosensitivity. A correct questionnaire should be
786conducted and, although not so important in typical
787phototoxic cases, complementary tests including
788photopatch and photoprovocation tests may contribute
789to the final etiologic diagnosis and, consequently, allow an
790adequate patient advice concerning further eviction of the




793Ammoury A, Michaud S, Paul C, Prost-Squarcioni C, Alvarez F, Lamani L,
794Launay F et al (2008) Photodistribution of blue-gray
Phototoxic Dermatitis 18 11
Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD
Page Number: 0 Date:1/11/11 Time:12:55:50
795 hyperpigmentation after amiodarone treatment. Molecular character-
796 ization of amiodarone in the skin. Arch Dermatol 144:92–96
797 Arias-Santiago S, Fernande´z-Pugnaire M, Anamza´n-Fernande´z F,
798 Serrano-Franco C, Serrano-Ortega S (2009) Phytophotodermatitis
799 due to Ruta graveolens prescribed for fibromyalgia. Rheumatol
800 48(11):1401
801 Auffret N, Janssen F, Chevalier P, Guillemain R, Amrein C, Le Beller C
802 (2006) Photosensibilisation au voriconazole. Ann Dermatol Venereol
803 133:330–332
804 Bakkum R, Heule F (2002) Results of photopatch testing in Rotterdam
805 during a 10-year period. Br J Dermatol 146:275–279
806 Baran R, Juhlin L (2002) Photoonycholysis. Photodermatol Photo-
807 immunol Photomed 18:202–207
808 Barbaud A, Collet E, Martin S, Granel F, Tre´chot P, Lambert D, Schmutz J
809 (2001a) Contact sensitization to chlorproe´thazine can induce persis-
810 tent light reaction and cross photoreactions to other phenothiazines.
811 Contact Dermatitis 44:373
812 Barbaud A, Gonc¸alo M, Bircher A, Bruynzeel D (2001b) Guidelines for
813 performing skin tests with drugs in the investigation of cutaneous
814 adverse drug reactions. Contact Dermatitis 45:321–328
815 Be´ani J (2009) Les photosensibilisations graves. Ann Dermatol Venereol
816 136:76–83
817 Berne B, Ros A (1998) 7 years experience of photopatch testing with
818 sunscreen allergens in Sweden. Contact Dermatitis 38:61–64
819 Bruynzeel D, Ferguson J, Andersen K, Gonc¸alo M, English J, Goossens A,
820 Holzle E et al (2004) Photopatch testing: a consensus methodology
821 for Europe. J Eur Acad Dermatol Venereol 18:679–682
822 Bryden A, Moseley H, Ibbotson S, Chowdhury M, Beck M, Bourke J,
823 English J et al (2006) Photopatch testing of 1115 patients: results of
824 the U.K. multicentre photopatch study group. Br J Dermatol
825 155:737–747
826 Cardoso J, Canelas M, Gonc¸alo M, Figueiredo A (2009) Photopatch
827 testing with an extended series of photoallergens. A 5-year study.
828 Contact Dermatitis 60:314–319
829 Chang C, Chang J, Hui C, Yang C (2009) Severe photosensitivity reaction
830 to Vandetanib. J Clin Oncol 27(27):114–115
831 Cohen P (2009) Photodistributed erythema multiforme:paclitaxel-
832 related, photosensitive conditions in patients with cancer. J Drugs
833 Dermatol 8:61–64
834 Collins P, Ferguson J (1994) Photoallergic contact dermatitis to
835 oxybenzone. Br J Dermatol 131:124–129
836 Correia O, Delgado L, Barros M (1994) Bullous photodermatosis after
837 lomefloxacin. Arch Dermatol 130(6):808–809
838 Cowen E, Nguyen J, Miller D, Mcshane D, Arron S, Prose N, Turner M
839 et al (2010) Chronic phototoxicity and aggressive squamous cell
840 carcinoma of the skin in children and adults during treatment with
841 voriconazole. J Am Acad Dermatol 62:31–37
842 Cummins R,Wagner-Weiner L, Paller A (2000) Pseudoporphyria induced
843 by celecoxib in a patient with juvenile rheumatoid arthritis.
844 J Rheumatol 27:2938–2940
845 Darvay A, White I, Rycroft R, Jones A, Hawk J, McFadden J (2001)
846 Photoallergic contact dermatitis is uncommon. Br J Dermatol
847 145:597–601
848 Devleeschouwer V, Roelandts R, Garmyn M, Goossens A (2008) Allergic
849 and photoallergic contact dermatitis from ketoprofen: results of
850 (photo) patch testing and follow-up of 42 patients. Contact Derma-
851 titis 58:159–166
852 Emmert B, Schauder S, Palm H, Haliier E, Emmert S (2007) Disabling
853 work-related persistent photosensitivity following photoallergic con-
854 tact dermatitis from chlorpromazine and olaquindox in a pig
855 breeder. Ann Agric Environ Med 14:329
856Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, Roujeau J
857(2006) Terbinafine-induced subacute cutaneous lupus
858erythematosus. Dermatology 212:59–65
859Ferguson J (1999) Drug and chemical photosensitivity. In: Hawk’s
860photodermatology, 1st edn. Oxford University Press, New York,
861pp 155–169
862Figueiredo A (1994) Fotossensibilidade aos anti-inflamato´rios na˜o
863estero´ides. Estudo fisiopatolo´gico (Thesis). Coimbra, Portugal
864Foti C, Bonamonte D, Conserva A, Stingeni L, Lisi P, Lionetti N, Rigano L
865et al (2008) Allergic and photoallergic contact dermatitis from
866ketoprofen: evaluation of cross-reactivities by a combination of
867photopatch testing and computerized conformational analysis.
868Curr Pharm Des 14(27):2833–2839
869Frick M, Soler-Palacin P, Nalda A, Guarmer M, Nadal C (2010) Photo-
870sensitivity in immunocompromised patients receiving long-
871term therapy with oral voriconazole. Pediatr Infect Dis J 29(5):
872480–481
873Fujimoto N, Danno K, Wakabayashi M, Uenishi T, Tanaka T (2009)
874Photosensitivity with eosinophilia due to ambroxol and UVB. Con-
875tact Dermatitis 60:110–113
876Gonc¸alo M (1998) Explorations dans les photo-allergies
877me´dicamenteuses. Em GERDA.Progre`s en Dermato-Allergologie.
878Nancy/John Libbey Eurotext, pp 67–74
879Gonc¸alo M (2004) Dermatitis por plantas y maderas. In: Em Conde-
880Salazar Go´mez L, Ancona-Alayo´n A (eds) Dermatologia profes-
881sional. Aula Me´dica Ediciones, Madrid, pp 193–210
882Gonc¸alo M (2010) Photopatch testing. In: Johanssen JD, Frosch P,
883Leppoitevin J-P (eds) Textbook of contact dermatitis, 5th edn.
884Springer, Berlin/Heidelberg
885Gonc¸alo M, Figueiredo A (1992) Photopatch testing with nonsteroidal
886anti-inflammatory drugs. Em Proceedings of the 1st european sym-
887posium of contact dermatitis, Brussels, pp 25
888Gonc¸alo S, Correia C, Couto J, Gonc¸aloM (1989) Contact and photocontact
889dermatitis from Ruta chalepensis. Contact Dermatitis 21(3):200–201
890Gonc¸alo M, Figueiredo A, Tavares P, Ribeiro C, Teixeira F, Baptista
891A (1992) Photosensitivity to piroxicam: absence of cross-reaction
892with tenoxicam. Contact Dermatitis 27(5):287–290
893Gonc¸alo M, Domingues J, Correia O, Figueiredo A (1999) Fotossen-
894sibilidad a flutamida. Boletim Informativo del GEIDC 29:45–48
895Gregoriou S, Karagiorga T, Stratigos A, Volonakis K, Kontochristopoulos G,
896Rigopoulos D (2008) Photo-onycholysis caused by olanzapine and
897aripiprazole. J Clin Psychopharmacol 28:219–220
898Hariva T, Kitamura K, Osawa J, Ikezawa Z (1993) A cross-reaction
899between piroxicam-photosensitivity and thiosalicylate hypersensitiv-
900ity in lymphocyte proliferation test. J Dermatol Sci 5(3):165–174
901Hawk J (1999) Photodermatology, 1st edn. Oxford University Press,
902New York
903Hawk J (2004) Chronic actinic dermatitis. Photodermatol
904Photoimmunol Photomed 20:312–314
905Hindse´n M, Isaksson M, Persson L, Zimersson E, Bruze M (2004)
906Photoallergic contact dermatitis from ketoprofen induced by drug-
907contaminated personal objects. J Am Acad Dermatol 50:215–219
908Imai S, Atarashi K, Ikesue K, Akiyama K, Tokura Y (2005) Establishment
909of murine model of allergic photocontact deermatitis to ketoprofen
910and characterization of pathogenic T cells. J Dermatol Sci 41:127–136
911Jensen A, Thomsen H, Engebjerg M, Olesen A, Sorensen H, Karagas M
912(2008) Use of photosensitising diuretics and risk of skin cancer:
913a population based case-control study. Br J Cancer 99:1522–1528
914Karimian-Teherani D, Kinaciyan T, Tanew A (2008) Photoallergic contact
915dermatitis from Heracleum giganteum. Photodermatol Photo-
916immunol Photomed 24:99–101
1218 Phototoxic Dermatitis
Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD
Page Number: 0 Date:1/11/11 Time:12:55:50
917 Katsarou A, Makris M, Zarafonitis G, Lagogianni E, Gregoriou S,
918 Kalogeromitros D (2008) Photoallergic contact dermatitis: the
919 15-year experience of a tertiary reference center in a sunny Mediter-
920 ranean city. Int J Immunopathol Pharmacol 21:725–727
921 Kerr A, Ferguson J, Ibbotson S (2007) Acute phototoxicity with urticarial
922 features during topical 5-aminolaevulinic acid photodynamic
923 therapy. Clin Exp Dermatol 32:201–202
924 Kerr A, Muller F, Ferguson J, Dawe R (2008a) Occupational carprofen
925 photoallergic contact dermatitis. Br J Dermatol 159:1303–1308
926 Kerr A,Woods J, Ferguson J (2008b) Photocontact allergic and phototoxic
927 studies of chlorproethazine. Photodermatol Photoimmunol
928 Photomed 24:11–15
929 Kimura M, Kawada A (1998) Photosensitivity induced by lomefloxacin
930 with cross-photosensitivity to ciprofloxacin and fleroxacin. Contact
931 Dermatitis 38:130
932 Klecak G, Urbach F, Urwyler H (1997) Fluoroquinolone antibacterials
933 enhance UVA-induced skin tumors. J Photochem Photobiol
934 B 37:174–181
935 Kochs C, Mu¨hlensta¨dt E, Neumann N, Hanneken S (2009) Solarium-
936 induced pseudoporphyria and variegate porphyria as rare differential
937 diagnoses of porphyria cutanea tarda. Hautarzt 60:790–793
938 Kurumajin Y, Shono M (1992) Scarified photopatch testing in
939 lomefloxacin photosensitivity. Contact Dermatitis 26:5–10
940 La Cuadra-Oyanguren J, Pe´rez-Ferriols A, Lecha-Carralero M, Gime´nez-
941 Arnau A, Ferna´ndez-Redondo V, Ortiz de Frutos F, Silvestre-
942 Salvador J et al (2007) Resultdos y evaluacio´n del fotoparche en
943 Espan˜a: hacia una nueva baterı´a esta´nder de fotoalergenos. Actas
944 Dermosifiliogr 98:96–101
945 Lasa Elgezua O, Gorrotxategi P, Gardeazabal Gracia J, Rato´n Nieto J, Pe´rez J
946 (2004) Photoallergic hand eczema due to benzydamine. Eur
947 J Dermatol 14(1):69–70
948 LeCoz C, Bottlaender A, Scrivener J, Santinelli F, Cribier B, Heidei E,
949 Grosshans E (1998) Photocontact dermatitis from ketoprofen and
950 tiaprofenic acid: cross-reactivity study in 12 consecutive patients.
951 Contact Dermatitis 38:245–252
952 Leonard F, Adamski H, Bonnevalle A, Bottlaender A, Bourrain J,
953 Goujon-Henry G, Leroy D et al (2005) E´tude prospective
954 multicentrique 1991–2001 de la batterie standard des photopatch-
955 tests de la Socie´te´ Franc¸aise de Photodermatologie. Ann Dermatol
956 Venereol 132:313–320
957 Lhiaubet-Vallet V, Bosca F, Miranda M (2009) Photosensitized DNA dam-
958 age: the case of fluoroquinolones. Photochem Photobiol 85:861–868
959 Lovell C (2000) Phytophotodermatitis. In: Avalos J, Maibach HI (eds)
960 Dermatological botany. CRC Press, Boca Raton, pp 51–65
961 Lovell C, Cronin E, Rhodes E (1986) Photocontact urticaria from chlor-
962 promazine. Contact Dermatitis 14:290–291
963 Lowe N (2006) An overview of ultraviolet radiation, sunscreens and
964 photo-induced dermatosis. Dermatol Clin 24:9–17
965 Marrot L, Belaı¨di J, Jones C, Perez P, Riou L, Sarasin A, Meunier J (2003)
966 Molecular responses to photogenotoxic stress induced by the antibi-
967 otic lomefloxacin in human skin cells: from DNA damage to apo-
968 ptosis. J Invest Dermatol 121:596–606
969 McCarthy K, Playforf E, Looke D, Whitby M (2007) Severe photosensi-
970 tivity causing multifocal squamous cell carcinomas secondary to
971 prolonged voriconazole therapy. Clin Infect Dis 44:e55–e56
972 Miller D, Cowen E, Nguyen J, McCalmont T, Fox L (2010) Melanoma
973 associated with long-term voriconazole therapy: a new manifestation
974 of chronic photosensitivity. Arch Dermatol 146(3):300–304
975 Mu¨ller L, Kasper P, Kersten B, Zhang J (1998) Photochemical genotoxicity
976 and photochemical carcinogenesis – two sides of a coin? Toxicol Lett
977 102–103:383–387
978Neumann N, Holzle E, Lehmann P, Benedikter S, Tapernoux B, Plewig G
979(1994) Patterns analysis of photopatch test reactions. Photodermatol
980Photoimmunol Photomed 16:65–73
981NeumannN, Holzle E, Plewig G, Schwatz T, Pannizzon R, Breit R, Ruzicka
982T et al (2000) Photopatchtesting: the 12-year experience of the
983german, Austrian and swiss photopatch test group. J Am Acad
984Dermatol 42:183–192
985Neves B, CruzM, Francisco V, Gonc¸aloM, Figueiredo A, Duarte C, LopesM
986(2008) Differential modulation of CXCR4 and CD40 protein levels
987by skin sensitizers and irritants in the FSCD cell line. Toxicol Lett
988177:74–82
989Oliveira H, Gonc¸alo M, Figueiredo A (1996) Photosensitivity from
990lomefloxacine. A clinical and photobiological study. Photodermatol
991Photoimmunol Photomed 16:116–120
992Passier A, Smits-van Herwaarden A, van Puijenbroek E (2004) Photo-
993onycholysis associated with the use of doxycycline. BMJ 329:265
994Pe´rez-Bustillo A, Sa´nchez-Sambucety P, Sua´rez-Amor O, Rodrı´iguez-
995Prieto M (2008) Torasemide-induced pseudoporphyria. Arch
996Dermatol 144(6):812–813
997Pigatto P, Bigardi A, Legori A, Valsecchi R, Picardo M (1996) Cross
998reactions in patch testing and photopatch testing with ketoprofen,
999tiaprofenic acid and cinnamic aldehyde. Am J Contact Dermat
10007:220–223
1001Pigatto P, Guzzi G, Schena D, Guarrera M, Foti C, Francalanci S,
1002Cristaudo A et al (2008) Photopatch tests: an Italian multicentre
1003study from 2004 to 2006. Contact Dermatitis 59(2):103–108
1004Placzek M, Eberlein-ko¨nig B, Przybilla B (1999) Association between
1005actinic keratoses and potentially photosensitizing drugs. N Engl
1006J Med 341:1474–1475
1007Schmutz J, Barbaud A, Tre´chot P (2006) Pseudoporphyria and coxib. Ann
1008Dermatol Venereol 133:213
1009Schmutz J, Barbaud A, Tre´chot P (2008) Ciprofloxacin and
1010pseudoporphyria. Ann Dermatol Venereol 135(11):804
1011Seto Y, Ochi M, Onoue S, Yamada S (2010) High-throughput screening
1012strategy for photogenotoxic potential of pharmaceutical substances
1013using fluorescent intercalating dye. J Pharm Biomed Anal 52(5):
1014781–786
1015Sheuer E, Warshaw E (2006) Sunscreen allergy: a review of epidemiology,
1016clinical characteristics, and responsible allergens. Dermatitis 17:3–11
1017Sontheimer R, Henderson C, Grau R (2008) Drug-induced subacute
1018cutaneous lupus erythematosus: a paradigm for bedside-to-bench
1019patient-oriented translational clinical investigation. Arch Dermatol
1020Res 301(1):65–70
1021Timmer-de Mik L, Kardaun S, Krammer M, Hayes D, Bousema M (2009)
1022Imatinib-induced pseudoporphyria. Clin Exp Dermatol 34(6):705–707
1023Tokura Y, Seo N, Fujie M, Takigawa M (2001) Quinolone-
1024photoconjugated major histocompatibility complex class II-binding
1025peptides with lysine are antigenic for T cells mediating murine
1026quinolone photoallergy. J Invest Dermatol 117(5):1206–1211
1027Urbina F, Barrios M, Sudy E (2006) Photolocalized purpura during
1028ciprofloxacin therapy. Photodermatol Photoimmunol Photomed
102922:111–112
1030Vassileva S, Matev G, Parish L (1998) Antimicrobial photosensitive reac-
1031tions. Arch Intern Med 158:1993–2000
1032Vilaplana J, Romaguera C, Azo´n A, Lecha M (1990) Flutamide photosen-
1033sitivity-residual vitiliginous lesions. Contact Dermatitis 38:68–70
1034Wagner A, Wu J, Hansen R, Nigg H, Beiere R (2002) Bullous phytopho-
1035todermatitis associated with high natural concentrations of
1036furanocoumarins in limes. Am J Contact Dermat 13(1):10–14
1037Walker S, Ead R, Beck M (2006) Occupational photoallergic contact
1038dermatitis in a pharmaceutical worker manufacturing carprofen,
Phototoxic Dermatitis 18 13
Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD
Page Number: 0 Date:1/11/11 Time:12:55:50
1039 a canine nonsteroidal anti-inflammatory drug. Br J Dermatol
1040 154:551–577
1041 Waters A, Sandhu D, Lowe G, Ferguson J (2009) Photocontact allergy to
1042 PABA: the need for continous vigilance. Contact Dermatitis
1043 60(3):172–173
1044Yazici A, Baz K, Ikizoglu G, Kokturk A, Uzumlu H, Tataroglu C (2004)
1045Celecoxib-induced photoallergic drug eruption. Int J Dermatol
104643(6):459–461
1047Zeeli T, David M, Trattner A (2006) Photopatch tests: any news under the
1048sun? Contact Dermatitis 55:305–307
1418 Phototoxic Dermatitis
Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD
Page Number: 0 Date:1/11/11 Time:12:55:50
Author Query Form
Textbook of Kanerva’s Occupational Skin Diseases
Chapter No.: 18
___________________________________________________________________________
Query Refs. Details Required Author’s response
AU1 Kindly confirm the organization division of the
author “Margarida Gonc¸alo.”
AU2 Please check if edit to the sentence starting: ‘‘Apart
from exogenous....’’ is okay.
AU3 Please check if change from ‘‘thiomersal’’ to
‘‘thimerosal’’ is okay here and in subsequent
occurrences.
AU4 In the sentence “In most reports… “5,6%” has been
changed to “5.6%.” Please check if OK.
AU5 Please specify the year “2008a” or “2008b” for the
citation “Kerr et al. 2008.”
AU6 Please check if the edit to the sentence starting
“Although in vitro .....” is OK.
AU7 Please specify the year “2001a” or “2001b” for ref.
“Barbaud et al. 2001.”
AU8 “Barbaud et al. 2001a, 2001b,” “Kerr et al. 2008a,
2008b” are not cited in the text. Please provide.
